TAKN Stock Chart & Stats
$298.00
$0.00(0.00%)
At close: 4:00 PM EDT
$298.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$200.00 - $320.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$974.11B
Enterprise Value$79.01K
Total Cash (Recent Filing)$527.58B
Total Debt (Recent Filing)$4.94T
Price to Earnings (P/E)129.5
Beta0.05
Next Earnings
Oct 29, 2026EPS Estimate
2.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)57.57
Shares Outstanding3,204,095,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)1.19
Price to Sales (P/S)1.94
P/FCF Ratio14.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$361.99Price Target Upside21.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)6.5
Revenue Forecast (FY)$499.99B
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline And Regulatory MomentumMultiple late-stage wins and near-term regulatory events materially de-risk growth profile: China ORZEYFUL approval, a U.S. priority review for rusfertide and zasocitinib Phase III success create several independent commercialization opportunities that can offset LOE and mature-product declines over the medium term if launches are executed well.
Manageable Leverage And Solid Balance-sheet PostureA balanced capital structure with debt-to-equity around 0.6–0.7 provides financial flexibility typical of large pharma. This reduces refinancing and solvency risk, supports continued R&D and launch funding, and allows the company to pursue pipeline investments or targeted M&A without overly constraining cash flow for operations or shareholder returns.
Committed Free Cash Flow Guidance And Transformation ProgramManagement reiterated a sizable FCF target and is executing a transformation program to generate savings for launches and pipeline investment. A clear FCF target combined with cost-transformation initiatives supports sustainable funding for new product commercialization, dividends and R&D over the next several quarters if delivery remains on track.
Bears Say
Slowing Underlying Organic GrowthUnderlying sales and core operating profit declined on a constant-currency basis, indicating the company remains exposed to structural demand pressures and LOE in mature products. Reliance on FX tailwinds and one-offs masks true organic momentum, which must be restored by successful launches to sustainably drive growth.
Thin Net Margins And Low Returns On EquityAlthough operating profitability (EBITDA) is healthy, conversion to net income is weak due to below-the-line items, taxes and amortization. Persistently low net margins and ROE imply inefficient capital deployment and limit the company's ability to generate attractive returns for shareholders unless structural cost or capital-allocation improvements occur.
New Launches Small Vs. LOE And Portfolio Erosion RiskFast-growing launches are still a small share of sales, so they are currently insufficient to offset generic erosion and LOE in key products. Scaling these launches into meaningful revenue will take time and execution, leaving the company exposed to near-to-medium-term revenue pressure if launches or market access are slower than planned.
Takeda Pharmaceutical Company News
TAKN FAQ
What was Takeda Pharmaceutical Company’s price range in the past 12 months?
Takeda Pharmaceutical Company lowest stock price was $200.00 and its highest was $320.00 in the past 12 months.
What is Takeda Pharmaceutical Company’s market cap?
Takeda Pharmaceutical Company’s market cap is $974.11B.
When is Takeda Pharmaceutical Company’s upcoming earnings report date?
Takeda Pharmaceutical Company’s upcoming earnings report date is Oct 29, 2026 which is in 81 days.
How were Takeda Pharmaceutical Company’s earnings last quarter?
Takeda Pharmaceutical Company released its earnings results on Jul 30, 2026. The company reported $3.856 earnings per share for the quarter, beating the consensus estimate of $2.896 by $0.96.
Is Takeda Pharmaceutical Company overvalued?
According to Wall Street analysts Takeda Pharmaceutical Company’s price is currently Undervalued.
Does Takeda Pharmaceutical Company pay dividends?
Takeda Pharmaceutical Company does not currently pay dividends.
What is Takeda Pharmaceutical Company’s EPS estimate?
Takeda Pharmaceutical Company’s EPS estimate is 2.47.
How many shares outstanding does Takeda Pharmaceutical Company have?
Takeda Pharmaceutical Company has 3,204,095,200 shares outstanding.
What happened to Takeda Pharmaceutical Company’s price movement after its last earnings report?
Takeda Pharmaceutical Company reported an EPS of $3.856 in its last earnings report, beating expectations of $2.896. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Company?
Currently, no hedge funds are holding shares in MX:TAKN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Takeda Pharmaceutical Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$361.99 (21.47% Upside)
$361.99 (21.47% Upside)
Blogger Sentiment
Neutral
MX:TAKN Sentiment 67%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.59%
12-Months-Change
Fundamentals
Return on Equity
3.66%
Trailing 12-Months
Asset Growth
-0.60%
Trailing 12-Months
Company Description
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
TAKN Company Deck
TAKN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balances clear operational and clinical momentum against near-term financial and timing headwinds. Financials benefitted materially from FX (+10.2% revenue at actual FX) and management reiterated full-year free cash flow guidance (JPY 650–750 billion) and execution of a transformation program. The quarter highlighted major clinical wins and imminent launches (ORZEYFUL, rusfertide, zasocitinib) and encouraging oncology and specialty pipeline readouts, which underpin medium-term growth confidence. Offsetting this, underlying revenue and core profit declined slightly at constant currency (-0.5% CER), core EPS fell 11.8% at CER (tax-driven), operating cash flow was weaker in Q1 due to working capital effects, and some margin improvement was driven by one-offs and FX. Takeda emphasized readiness for launches, continued transformation, and a December Capital Markets Day to provide further visibility.View all MX:TAKN earnings summariesTAKN Stock 12 Month Forecast
Average Price Target
$361.99
▲(21.47% Upside)